Abstract
68Ga-DOTATATE is a well-established, positron-emitting, somatostatin receptor-binding radiopharmaceutical. We present an unusual case of transiently increased blood pool uptake of 68Ga-DOTATATE in a patient with well-differentiated stage IV neuroendocrine tumor, with Ki-67 <2% (WHO grade 1) maintained on lanreotide. During serial 68Ga-DOTATATE PET/CT examinations, increased blood pool accumulation of presumably unbound 68Ga was demonstrated, which could impact the Kenning score and lead to a false treatment response assessment.
Original language | English (US) |
---|---|
Pages (from-to) | 137-139 |
Number of pages | 3 |
Journal | Clinical nuclear medicine |
Volume | 47 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1 2022 |
Keywords
- Ga-DOTATATE PET/CT
- blood pool
- neuroendocrine tumor
- somatostatin receptor
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging